OncoMatch/Clinical Trials/NCT05425004
Cabozantinib for Patients With Recurrent or Progressive Meningioma
Is NCT05425004 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cabozantinib for meningioma.
Treatment: Cabozantinib — A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage I, II, III (WHO)
All World Health Organization (WHO) grades (I, II and III) are allowed. Patients must have measurable disease by iRANO criteria
Prior therapy
Must have received: standard therapy (radiation, surgery)
All patients must have developed recurrent disease or progressive disease after receiving standard therapy (e.g., radiation or surgery) > 6 months ago or have been deemed ineligible to receive these therapies.
Cannot have received: cabozantinib (cabozantinib)
Prior treatment with cabozantinib.
Lab requirements
Blood counts
Absolute Neutrophil Count ≥ 1.5 x 10^9 / L without G-CSF support; Platelet Count ≥ 100 x 10^9 / L without transfusion; Hemoglobin ≥ 9 g/dL without transfusion within 7 days prior to screening assessment.
Kidney function
≥ 30 ml/min according to the Cockcroft-Gault formula.
Liver function
Total bilirubin ≤ 1.5 x ULN; AST ≤ 3 x ULN without liver metastasis; ALT ≤ 3 x ULN without liver metastasis; AST or ALT ≤ 5 x ULN for patients with liver metastasis; Gilbert's syndrome allowed if total bilirubin ≤ 3 x ULN.
Cardiac function
Ejection fraction (EF) > 50% by ECHO or MUGA if ECHO insufficient; QTcF ≤ 500 ms within 14 days of study registration (if initial QTcF >500 ms, average of two additional EKGs ≤ 500 ms required); Prothrombin time (PT)/INR or PTT < 1.3x ULN.
Adequate hematologic function: ANC ≥ 1.5 x 10^9 / L without G-CSF support; Platelet Count ≥ 100 x 10^9 / L without transfusion; Hemoglobin ≥ 9 g/dL without transfusion within 7 days prior to screening assessment. Adequate renal function: ≥ 30 ml/min according to the Cockcroft-Gault formula. Adequate hepatic function including: Total bilirubin ≤ 1.5 x ULN; AST ≤ 3 x ULN without liver metastasis; ALT ≤ 3 x ULN without liver metastasis; AST or ALT ≤ 5 x ULN for patients with liver metastasis; Gilbert's syndrome allowed if total bilirubin ≤ 3 x ULN. Serum albumin ≥ 2.8 g/dL. PT/INR or PTT < 1.3x ULN. Ejection fraction (EF) > 50% by ECHO or MUGA if ECHO insufficient. QTcF ≤ 500 ms within 14 days of study registration (if initial QTcF >500 ms, average of two additional EKGs ≤ 500 ms required).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Miami Cancer Institute at Baptist Health, Inc. · Miami, Florida
- Memorial Sloan Kettering Cancer Center · New York, New York
- Vanderbilt University Medical Center · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify